<code id='6934620CF0'></code><style id='6934620CF0'></style>
    • <acronym id='6934620CF0'></acronym>
      <center id='6934620CF0'><center id='6934620CF0'><tfoot id='6934620CF0'></tfoot></center><abbr id='6934620CF0'><dir id='6934620CF0'><tfoot id='6934620CF0'></tfoot><noframes id='6934620CF0'>

    • <optgroup id='6934620CF0'><strike id='6934620CF0'><sup id='6934620CF0'></sup></strike><code id='6934620CF0'></code></optgroup>
        1. <b id='6934620CF0'><label id='6934620CF0'><select id='6934620CF0'><dt id='6934620CF0'><span id='6934620CF0'></span></dt></select></label></b><u id='6934620CF0'></u>
          <i id='6934620CF0'><strike id='6934620CF0'><tt id='6934620CF0'><pre id='6934620CF0'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:28
          Vertex Pharmaceuticals Inc. building
          Craig F. Walker/The Boston Globe

          Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease. 

          The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

          advertisement

          “The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Novo Nordisk gets FDA approval to tout heart benefits of Wegovy
          Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

          AmandaAndrade-Rhoades/APU.S.regulatorsapprovedalabelexpansionforNovoNordisk’sobesitydrugWegovytotout

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

          KristofferTripplaar/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiot